Jennifer Silva discusses the importance of discussing black box warnings when utilizing JAK inhibitors in patients with vitiligo.
Jennifer Silva discusses the importance of discussing black box warnings when utilizing JAK inhibitors in patients with vitiligo.
Tristan Hasbargen, PA-C, a physician assistant at Dermatology Associates of Tallahassee in Tallahassee, Florida, discusses the treatment of vitiligo, emphasizing the importance of setting patient
David Rosmarin, MD, the chair of the Department of Dermatology at Indiana University in Indianapolis, discusses results from a pooled subgroup analysis of the 104-week
Dr. Desai discusses treating patients with vitiligo with ruxolitinib cream 1.5% in the face and neck area.
Chantel Hillestad discusses treatment options for vitiligo on the hands and how UV exposure can increase the presentation of vitiligo.
Chantel Hillestad, RN, MSN, DCNP, FNP-C, shares clinical experience using ruxolitinib to restore pigmentation in vitiligo patients across all age groups. Topics Covered: Ruxolitinib for
Dr. Desai discusses the efficacy and longevity of treatment with ruxolitinib cream 1.5% in patients with facial vitiligo based on a recent post-hoc analysis of
Dr. Seneschal discusses currently available topical JAKs for vitiligo, systemic JAKs being trialed to treat the condition in the future, and how JAKs can be
Jennifer Silva, APRN-DNP, outlines treatment options for patients with vitiligo who have not responded well to traditional therapies. Topics Covered: Challenges in vitiligo treatment Strategies
Iltefat Hamzavi, MD, and JCAD’s Editor-in-Chief, James Del Rosso, DO, discuss topical treatment considerations for patients with vitiligo when using topical ruxolitinib cream, including topical
Gina Mangin discusses effective treatment practice for patients with vitiligo centered around providing encouragement and motivation throughout the process.
Dr. Rosmarin discusses his vitiligo session from November’s Masterclasses in Dermatology Meeting, in which he reviewed recent insights on maintaining and building upon initial treatment
Gina Mangin, MPAS, PA-C, discusses the role of light box therapy in vitiligo management, with a focus on setting clear expectations around treatment timelines and
Shanna Miranti, MPAS, PA-C, discusses prescribing considerations for topical ruxolitinib in patients with vitiligo, emphasizing the importance of prior treatment attempts with topical corticosteroids and
Nada Elbuluk, MD, discusses the importance of assessing psychological comorbidities in patients with vitiligo by gathering key social information, including daily activities, living situation, and
